Inventor · disambiguated record
James J. Campbell
Also filed as: CAMPBELL JAMES · CAMPBELL JAMES J · CAMPBELL JAMES JEFFERY
14 granted patents·16 pending applications·110 citations·filing 1979–2025
91Inventor score
Files withCHEMOCENTRYX INC21HARRISON JEFFREY K2MILLENNIUM PHARM INC1PIPELINE SUPPLY & SERVICE LLC1Pipeline Supply and Service LLC1
Top patents by PatentIndex Score
30 records- 0197US11045469B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Jun 29, 2021·5 cites·18 claims
- 0295US10792360B1Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Oct 6, 2020·6 cites·16 claims
- 0392US9787210B2Precharging apparatus and power converterROCKWELL AUTOMATION TECH INC·Filed 2015·Granted Oct 10, 2017·6 cites·13 claims
- 0490US11304952B2Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitorCHEMOCENTRYX INC·Filed 2018·Granted Apr 19, 2022·11 cites·16 claims
- 0589US6245332B1Modulation of systemic memory T cell traffickingUNIV LELAND STANFORD JUNIOR·Filed 1999·Granted Jun 12, 2001·65 cites·15 claims
- 0686US11154556B2Methods of treating solid tumors with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 26, 2021·3 cites·16 claims
- 0784US11020394B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2019·Granted Jun 1, 2021·1 cites·8 claims
- 0883US11986466B2Methods of treating solid tumors with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted May 21, 2024·1 cites·4 claims
- 0983US11464786B2CXCR7 inhibitors for the treatment of cancerCHEMOCENTRYX INC·Filed 2019·Granted Oct 11, 2022·2 cites·20 claims
- 1080US2024285593A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitorCHEMOCENTRYX INC·Filed 2024·Application pending·0 cites
- 1176US2023263784A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitorCHEMOCENTRYX INC·Filed 2023·Application pending·0 cites
- 1275US11207294B2Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2CHEMOCENTRYX INC·Filed 2019·Granted Dec 28, 2021·1 cites·6 claims
- 1375US2024100041A1Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodiesCHEMOCENTRYX INC·Filed 2023·Application pending·0 cites
- 1474US2025090543A1Cxcr7 inhibitors for the treatment of cancerCHEMOCENTRYX INC·Filed 2024·Application pending·0 cites
- 1573US6881406B2Modulation of systemic memory T cell traffickingMILLENNIUM PHARM INC·Filed 2001·Granted Apr 19, 2005·5 cites·14 claims
- 1672US2021322410A1Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
- 1771US11684606B2Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2CHEMOCENTRYX INC·Filed 2021·Granted Jun 27, 2023·0 cites·15 claims
- 1870US11883391B2Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodiesCHEMOCENTRYX INC·Filed 2021·Granted Jan 30, 2024·0 cites·8 claims
- 1970US2023404986A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitorHARRISON JEFFREY K·Filed 2023·Application pending·0 cites
- 2069US2023100102A1Cxcr7 inhibitors for the treatment of cancerCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 2166US2023023075A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitorCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 2263US2019275015A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitorCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 2362US2022241290A1Methods of treating solid tumors with ccr2 antagonistsCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
- 2455US2025283851A1Remote verification of calibrationPIPELINE SUPPLY & SERVICE LLC·Filed 2025·Application pending·0 cites
- 2554US2020297708A1Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 InhibitorHARRISON JEFFREY K·Filed 2020·Application pending·0 cites
- 2654US2021154292A1Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking AntibodiesCHEMOCENTRYX INC·Filed 2020·Application pending·0 cites
- 2754US2025076240A1Smart holiday detection and data storagePipeline Supply and Service LLC·Filed 2024·Application pending·0 cites
- 2854US2019269664A1Methods of treating solid tumors with ccr2 antagonistsCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 2953US2005169918A1Modulation of systemic memory T cell traffickingFiled 2005·Application pending·0 cites
- 3037US4246583AMultimode feed for a monopulse radarRCA CORP·Filed 1979·Granted Jan 20, 1981·4 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when James J. Campbell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →